Impact of elranatamab on quality of life: Patient‐reported outcomes from MagnetisMM ‐3
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19346 ↗Kurz gefasst
Klinische Studie in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Mohamad Mohty und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne University, Hôpital Saint-Antoine, and INSERM UMRS 938, Paris, France. Hauptthemen laut MEDLINE: Multiple Myeloma, Patient Reported Outcome Measures, Quality of Life. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
The physical and emotional burden of relapsed or refractory multiple myeloma (RRMM) has been strongly correlated with declining health‐related quality of life (QOL) in the patients it affects. This analysis evaluated patient‐reported outcomes (PROs) from B‐cell maturation antigen (BCMA)‐naive ( n = 123) and ‐exposed ( n = 64) patients with RRMM enrolled in the MagnetisMM‐3 study (NCT04649359) and treated with the humanized, bispecific BCMA‐CD3 antibody elranatamab. Patients received two step‐up doses of elranatamab (12 mg on day 1, 32 mg on day 4) before starting the full dose of 76 mg on day 8 (each cycle = 28 days). Global health status, functioning and symptom data were collected electronically using validated and myeloma‐specific questionnaires. Improvements in PROs occurred early, with marked reductions in pain and disease symptoms and notable improvements in patients’ outlook for their future health. Additionally, 40.2% of BCMA‐naive and 52.6% of BCMA‐exposed patients perceived their disease as ‘a little better’ or ‘much better’ by Cycle 1, Day 15. The results from this analysis demonstrated that elranatamab maintained or improved symptomology and general health status, regardless of prior BCMA‐directed therapy. Thus, in addition to its clinical benefits, elranatamab therapy may sustain or improve QOL in heavily pretreated patients with RRMM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sorbonne University, Hôpital Saint-Antoine, and INSERM UMRS 938, Paris, France.
- Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada.
- Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
- Pfizer Inc, New York, New York, USA.
- Pfizer Inc, Collegeville, Pennsylvania, USA.
ORCID-Profile: Mohamad Mohty, Nizar J Bahlis, Ajay K Nooka, Marco DiBonaventura
Förderung
- Pfizer
Zitieren
APA
Mohty, M., Bahlis, N. J., Nooka, A. K., DiBonaventura, M., Ren, J., & Conte, U. (2024). Impact of elranatamab on quality of life: Patient‐reported outcomes from MagnetisMM ‐3. British Journal of Haematology. https://doi.org/10.1111/bjh.19346
Vancouver
Mohty M, Bahlis NJ, Nooka AK, DiBonaventura M, Ren J, Conte U. Impact of elranatamab on quality of life: Patient‐reported outcomes from MagnetisMM ‐3. British Journal of Haematology. 2024. doi:10.1111/bjh.19346
BibTeX
@article{Mohty2024,
author = {Mohty, Mohamad and Bahlis, Nizar J and Nooka, Ajay K and DiBonaventura, Marco and Ren, Jinma and Conte, Umberto},
title = {Impact of elranatamab on quality of life: Patient‐reported outcomes from MagnetisMM ‐3},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19346}
}
EUVIMED